FDA Approves Revuforj® as First Menin Inhibitor for Acute Leukemia with KMT2A Translocation

CHMP Recommends Approval of Opdivo® Plus Yervoy® for First-Line Treatment of MSI-H/dMMR Metastatic Colorectal Cancer

ADDF Invests $1.18M to Standardize p-tau217 Blood Tests for Alzheimer’s Diagnosis

GSK Reports Positive Interim Results for DREAMM-7 Trial of Blenrep in Multiple Myeloma

Molbio Diagnostics Invests $30 Million in OptraSCAN to Revolutionize Digital Pathology

BioNTech Acquires Chinese Oncology Firm Biotheus for $950M

The Care and Protection of Children Trust

CPCT Launches Groundbreaking Initiative to Provide Lifelong Free Treatment for Children with Spinal Muscular Atrophy (SMA) in Karnataka

Early Comprehensive Genomic Profiling Improves Cancer Treatment Outcomes, Study Shows

EMA Reverses Decision, Recommends Limited Approval for Eisai and Biogen’s Alzheimer’s Drug Leqembi

Exact Sciences Unveils Advances in Multi-Cancer Early Detection with Cancerguard™ Test

MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Home
/
insight
/
details

Preserving Tomorrow’s Health: A Call to Action for Superbug Preparedness and Collaboration

NextEdge Admin

28 Jan 2024

3 min 52 sec

World Health Organization (WHO),antibiotics

Amidst the aftermath of the COVID-19 pandemic, a looming health crisis takes centre stage – the escalating menace of superbugs. These minuscule adversaries, armed with resistance to multiple drugs, pose a serious global threat to both health and economic stability. The World Health Organization (WHO) issues a stern warning, underscoring the surge of superbugs attributed to antimicrobial drug misuse, unsanitary conditions, and inadequate infection prevention. WHO estimates predict that, by 2050, multidrug-resistant pathogens could contribute to an annual death toll of approximately 10 million people.

Superbugs, evolving naturally, wreak havoc particularly in conditions where the immune system is compromised. Vulnerable populations, including patients with diabetes, severe burns, and HIV, face heightened susceptibility to infections by these drug-resistant microbes.

The WHO categorizes superbugs into three priority groups for the research and development (R&D) of new antibiotics. The first group encompasses Acinetobacter baumannii and Pseudomonas aeruginosa, the second group includes bacteria like Neisseria gonorrhoeae and Staphylococcus aureus, and the third group involves pathogens like Haemophilus influenzae and Shigella.

By understanding the genetic makeup and essential enzymes for superbug survival, researchers can develop precise drugs that specifically target those elements. Recent research endeavours focus on identifying essential enzymes for superbug survival with the goal of developing drugs that can inhibit these enzymes. Innovative approaches, such as AMR gene silencers like the CRISPR-Cas system designed to mute AMR genes, and ribosomal inhibitors that bind with ribosomal subunits, disrupting protein production and rendering bacteria defenceless, represent promising avenues. Efflux pump inhibitors, which impede the expulsion of antibiotics from bacterial cells, also play a significant role in ongoing research efforts.

Promising approaches, such as bio-nanotechnology, antimicrobial polymeric biomaterials, and combinational drug therapies, are also being explored. Natural products and metal nanoparticles show potential in the fight against superbugs.

Preventive measures are deemed critical, emphasizing proper hygiene practices, judicious use of antimicrobial drugs, and a reduction in unnecessary broad-spectrum treatments. Heightened awareness among healthcare professionals and the public is crucial to curb the inappropriate use of antimicrobials.

Looking ahead, the battle against superbugs demands a global effort, collaboration, and a commitment to preserving the efficacy of our medical arsenal. Advances in drug development, combined with preventive measures and an emphasis on overall health, offer hope in the ongoing fight against these resilient foes. It’s a call to action for a healthier, more resilient future.